Physician profile
Ibrahim Osman
NPI 1417225939
$19,031.90
in general payments reported to CMS, 2019-2025
35 companies · $3,815 in 2025
The $3,815 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,935 · 2020: $1,653 · 2021: $2,035 · 2022: $1,449 · 2023: $6,457 · 2024: $1,688 · 2025: $3,815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $7,519 · Food and Beverage: $4,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $7,518.72 |
| Food and Beverage | $4,441.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $6,922.24 | 2021-2025 | Micra, Attain Command + Surevalve, Aurora Ev-Icd Mri Surescan |
| Penumbra, INC. | $3,860.80 | 2022-2023 | Indigo System |
| Abbott Laboratories | $1,944.44 | 2022-2025 | Mitraclip, Pressurewire, Xience Skypoint |
| Medtronic Vascular, INC. | $1,260.43 | 2019-2020 | |
| Boston Scientific Corporation | $1,158.64 | 2019-2025 | Emblem Mri S-Icd |
| Abiomed | $462.07 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $359.78 | 2019-2022 | |
| Inari Medical, INC. | $313.52 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $299.56 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $250.00 | 2022 | |
| Edwards Lifesciences Corporation | $243.07 | 2022-2025 | Sapien 3 Ultra Resilia |
| Astrazeneca Pharmaceuticals Lp | $213.33 | 2019-2024 | Farxiga |
| Asahi Intecc USA, INC. | $179.92 | 2021 | |
| Cardiovascular Systems INC. | $168.30 | 2019-2022 | |
| Terumo Medical Corporation | $163.06 | 2020-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $148.66 | 2019-2024 | Lifevest |
| Kiniksa Pharmaceuticals, Ltd. | $135.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.16 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $109.06 | 2019 | |
| Chiesi USA, INC. | $107.69 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $81.09 | 2019-2023 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $77.55 | 2019-2023 | Seglentis, Livalo |
| Acist Medical Systems, INC. | $66.67 | 2022 | |
| Amgen INC. | $66.67 | 2019-2024 | Repatha |
| Pfizer INC. | $65.42 | 2019-2020 | |
| Bridgebio Pharma, INC. | $64.16 | 2025 | Attruby |
| Zoll Circulation INC | $48.27 | 2022 | |
| Biotronik INC. | $22.06 | 2024 | Amvia Edge |
| Philips North America LLC | $19.73 | 2022 | |
| Novo Nordisk INC | $19.33 | 2024 | Wegovy |
| Merck Sharp & Dohme LLC | $17.70 | 2022 | |
| Arbor Pharmaceuticals, INC. | $16.66 | 2019 | |
| Teleflex LLC | $15.33 | 2023 | Vascband |
| Alnylam Pharmaceuticals INC. | $13.70 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ibrahim Osman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.